Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sulfasalazine + thalidomide
- Development stage
- Preclinical
- Lead developer
- Assistance publique - Hôpitaux de Paris
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy of sulfasalazine and thalidomide that has been studied experimentally for inflammatory bowel disease. The combination showed additive effects in restoring lipid peroxidation and reducing myeloperoxidase and TNF-α levels toward normal in experimental models. This combination has also been considered for management of conditions like ankylosing spondylitis as an alternative to TNF inhibitors.
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))CRBN (Cereblon)PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on sulfasalazine + thalidomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sulfasalazine + thalidomide.